oncopeptides



INTERIM REPORT – Q1 2023

Providing clinical benefit to patients

Significant events

JANUARY-MARCH

- **Monica Shaw is appointed CEO** and takes office on the 4th of January, and Jakob Lindberg assumes role as Chief Scientific Officer.
- **Holger Lembrér is appointed CFO** and takes office on the 18th of January 2023.
- **Oncopeptides receives a research grant of SEK 3 M from Sweden´s Innovation Agency Vinnova**, as per 28th of March, to explore the PDC platform in solid tumors

EVENTS AFTER THE PERIOD

- **Oncopeptides issues warrants to utilize the first loan tranche from EIB.**

Financial overview

JANUARY-MARCH

- **Net sales** amounted to SEK 1.1 M (-)
- **Operating profit** amounted to SEK -72.7 M (-98.9)
- **Net profit** amounted to SEK -71.0 M (-98.6)
- **Profit per share,** before and after dilution, amounted to SEK -0.79 (-1.31)
- **Cash balances** at the end of the period amounted to SEK 253.9 M (194.3)

Selected Key Indicators

(SEK thousand)	2023 Jan-Mar	2022 Jan-Mar	2022 Jan-Dec	2021 Jan-Dec
Net sales	1 124	-	8 355	118 295
Operating profit	-72 740	-98 865	-349 350	-1 420 917
Profit after tax	-71 025	-98 587	-337 951	-1 430 317
Earnings per share before and after dilution (SEK)	-0,79	-1,31	-4,11	-19,00
Cash flow from operating activities	-88 997	-166 033	-420 509	-1 516 391
Cash at the end of the period	253 904	194 315	344 515	362 187
R&D costs/operating expenses, %	41%	67%	61%	46%

This publication is a translation of the original Swedish text. In the event of inconsistency or discrepancy between the Swedish version and this publication, the Swedish language version shall prevail.

Pepaxti providing clinical benefit to patients with Multiple Myeloma

The first quarter marked an important transition for Oncopeptides, establishing ourselves as a commercial organization. Our key priority this year is building the Pepaxti launch in Germany and initiating pricing and reimbursement discussions across Europe.

We have successfully hired team members in Germany with a broad set of skills, existing network, and experience to launch drugs within haematology and multiple myeloma. This has allowed us to increase the coverage of target physicians and raise the awareness and willingness to prescribe Pepaxti. We are leveraging our experience in Germany to consolidate our positioning of Pepaxti and finalize a launch sequence for the rest of Europe, and have interesting opportunities in our pre-clinical pipeline, advancing the PDC and SPiKE platforms towards the clinic. After the quarter we have extended the cash runway and refocused our spending and decided to utilize the first tranche of our loan facility with the European Investment Bank (EIB).

A key reason I joined Oncopeptides was the opportunity to launch Pepaxti, as I believe this is an important product for patients with multiple myeloma. Speaking with physicians in Germany and across Europe, I have received consistent feedback that more options are needed for patients who prioritize efficacy while maintaining their quality of life with a manageable treatment alternative. To address this unmet need, we aspire for Pepaxti to become the preferred treatment option in elderly patients with relapsed, refractory multiple myeloma.

Where physicians have begun to use Pepaxti, we have started to see a progression towards depth of prescribing and advocacy, with new physicians becoming speakers for us at peer-to-peer events. We have completed a first market access assessment for Europe, developed a market access strategy, and initiated pricing and reimbursement discussions in key markets. This enables us to do a targeted geographic expansion in Europe and provides the basis for go/no go commercial decisions in other geographies, as well as a launch sequence that protects our price and maximizes profitability. For key markets we will develop our own commercial model and for other European markets we will identify profitable partnerships. We have already initiated a partnership with Ariti in Greece where we have experienced significant interest from physicians who had been involved in our clinical studies.

The market authorizations in the EU and UK during the second half of 2022 have made it possible for us to extend patent protection for five years via Supplementary Protection Certificates (SPCs).

I am pleased to share that our submission to the European Medicines Agency regarding a type II variation to expand the market for Pepaxti and enable prescription in adult patients with multiple myeloma who have received at least two prior lines of therapies, is progressing well. We are now planning for a formal marketing authorization in Q3 2023.

With regards to our pipeline, we have received a Eurostars research grant of SEK 3 M from Sweden´s Innovation Agency Vinnova, to explore the development of new treatment options for glioblastoma, an aggressive and incurable form of brain cancer with an imminent need for more effective therapies. The grant allows exploratory research to better understand the potential of the PDC platform in solid tumours such as glio-blastoma. While Pepaxti and the PDC platform has been validated in multiple myeloma, preclinical data have also demonstrated a potential to expand the PDC platform into other haematological tumours such as lymphoma and acute myeloid leukemia (AML) and solid tumours such as mesothelioma, triple negative breast cancer, retinoblastoma and liver cancer. We will be exploring our strategic options in these spaces. We will also continue to advance our preclinical proof of concept for a novel synthetic small polypeptide based on our Small Polypeptide based innate Killer Engager platform (SPiKE). The compound is a Natural Killer (NK) cell engaging immunotherapy that uses the affibody technology. The compounds enable superior tissue penetration and immune cell activation, resulting in effective target cell killing and potentially less risk of immune system exhaustion. NK-cells are becoming increasingly important targets to avoid cytokine release syndrome (CRS), associated with T-cell activating immunotherapies such as checkpoint inhibitors, CAR-Ts and bispecific T-cell engagers (BiTEs). The small molecules enable synthetic production, which means that compounds can be produced on a larger scale through a much more efficient and less costly process. We have previously received a research grant to explore the SPiKE platform in multiple myeloma in collaboration with a world leading research consortium. The project is partly financed by Vinnova and qualified as a Eurostars program. We are exploring further indications given the flexibility of our platform to target any potential malignancy.

Oncopeptides has decided to utililze the first of three potential tranches of our loan facility with the EIB, amounting to EUR 10 million. This increases our flexibility during the commercialization of Pepaxti and enables us to further expand our business and create value for patients and shareholders. As well as continuous cost optimization, this is supporting our stable cash and equity position. With our projected sales trajectory and spending base we aim to be a profitable company within about 3 years.

This is the start of an exciting journey for Oncopeptides with a team of proud and highly passionate individuals who are excited to bring a valuable new treatment option in Pepaxti to patients with multiple myeloma. I would like to extend my gratitude to all shareholders, healthcare professionals, partners, and co-workers, who are making this possible. Together we are bringing hope through science.

Stockholm, May 4, 2023

Monica Shaw
CEO

Financial Overview

REVENUE
Net sales for the quarter amounted to SEK 1.1 M (-). Sales during the quarter related to Germany. See note 5.
Gross profit for the quarter amounted to SEK 1.1 M (-).

OPERATING EXPENSES
Operating expenses, excluding cost of goods sold, for the quarter amounted to SEK 73.9 M (98.9).

RESEARCH AND DEVELOPMENT EXPENSES
Research and development expenses amounted to SEK 30.1 M (65.8) for the quarter. Only a few clinical studies were ongoing during the quarter and the phase 3 study Ocean is in its final stage. The company has received repayments of SEK 22.9 M during the quarter related to previously closed clinical studies, which affected the costs in a positive way.

MARKETING AND SALES EXPENSES
Marketing and sales expenses amounted to SEK 23.5 M (10.0) for the quarter. The expenses during the quarter has been affected by the commercialization activities following the EU approval in August 2022.

GENERAL AND ADMINISTRATIVE EXPENSES
General and administrative expenses amounted to SEK 21.8 M (23.2) for the quarter.

EXPENSES FOR SHARE BASED INCENTIVE PROGRAMS
The costs for share based related incentive programs amounted to SEK 4.9 M (7.4) for the quarter; of which provisions and payments for social security related expenses amounted to SEK -0.2 M (0.3), and expenses relating to share-based remuneration amounted to SEK 5.1 M (7.1). The expenses have no cash impact in the current period. See note 7.

TAX AND EARNINGS
Net profit amounted to SEK -71.0 M (-98.6) for the quarter, corresponding to a loss per share, before and after dilution, of SEK -0.79 (-1.31) for the quarter.

CASH FLOW, INVESTMENTS AND FINANCIAL POSITION
Cash flow from operating activities amounted to SEK -89.0 M (-166.0) for the quarter.

Cash flow from
- Investment activities amounted to SEK -0.0 M (0.0) for the quarter.
- Financing activities amounted to SEK -1.8 M (-4.0) for the quarter.

Cash flow for the quarter amounted to SEK -90.8 M (-170.0).

Cash balances at the end of the period amounted to SEK 253.9 M (194.3). Cash balances include short term investments at an amount of SEK 75.5 M, which represents holdings on interest bearing accounts with a shorter term than three months

In the fourth quarter, a loan agreement was concluded with the European Investment Bank (EIB). The facility gives Oncopeptides access to an unsecured loan facility of up to EUR 30 M. The loan agreement is divided into three tranches, each with a maturity of five years, and made available if the company reaches certain milestones. If the company exercises the full loan facility, the EIB will be entitled to warrants equivalent to 2.8% of outstanding shares in Oncopeptides - in addition to interest on the loan amount. The loan can be used to support the continued clinical development and the company's commercial ventures.

Equity amounted to SEK 228.40 M (119.1) at the end of the period. Equity is in its entirety attributable to the Parent Company´s shareholders

EFFECTS OF COVID-19
Covid-19 is not deemed to have any material effects on the financial statements.

THE WAR IN UKRAINE
The situation in the Ukraine is not deemed to have any material effects on the financial statements.

GOING CONCERN
This interim report is issued based on the assumption of going concern for at least 12 months.

Given the EU Commission's approval in August, the successful directed share issue that closed last summer, access to the as yet unutilized commercial EIB loan, and the initiated commercialization in the EU, it is the assessment of the Board of Directors and the CEO that the Group will have the necessary liquidity for the continued operation of the business for at least the next twelve months.

Should decisive conditions not be met, for example by sales not developing as expected, the Group's continued operation might be at risk. This means that there are circumstances that may give rise to significant doubts about the company's ability to continue operations without additional financing.

The company deems other risks to be reflected as described in the annual report 2022.

EMPLOYEES
The number of FTE:s for the quarter was 59 (70).

PARENT COMPANY
Parent company operations are aligned with those of the Group, why the comments for the Group are also relevant for the Parent Company.

ONCOPEPTIDES SHARE
At the end of the period, the number of registered shares eligible for trading and votes in Oncopeptides amounted to 90,368,660.

AUDIT
This report has not been reviewed by the company's auditor.

Signatures

The Board and the CEO confirm that the interim report provides a true and fair reflection of the Group's and the Parent Company's operations, position and earnings and describes the material risks and uncertainty factors faced by the Parent Company and the companies within the Group.

Stockholm, May 4, 2023

Per Wold-Olsen
Chairman

Jenifer Jackson
Board member

Cecilia Daun-Wennborg
Board member

Per Samuelsson
Board member

Jarl Ulf Jungnelius
Board member

Brian Stuglik
Board member

Monica Shaw
CEO



Condensed consolidated statement of comprehensive income

SEK thousand	Note	2023 Jan-Mar	2022 Jan-Mar	2022 Jan-Dec	2021 Jan-Dec
Net sales	5	1 124	-	8 355	118 295
Cost of Goods Sold		-11	-	-6	-53 121
Gross profit		**1 113**	**-**	**8 349**	**65 174**
Research and development expenses		-30 067	-65 828	-217 657	-679 926
Marketing and distribution expenses		-23 466	-10 048	-58 102	-698 346
Administrative expenses		-21 801	-23 206	-84 093	-175 459
Other operating income/expenses		1 481	217	2 153	67 640
Total operating expenses		**-73 853**	**-98 865**	**-357 699**	**-1 486 091**
EBIT; Operating profit/loss		**-72 740**	**-98 865**	**-349 350**	**-1 420 917**
Net financial items		468	266	11 670	-455
EBT; Earnings before taxes		**-72 272**	**-98 599**	**-337 680**	**-1 421 372**
Income tax		1 247	12	-271	-8 946
Net profit		**-71 025**	**-98 587**	**-337 951**	**-1 430 317**
Other comprehensive income					
Items to be reclassified as profit or loss					
Translation variances		64	-294	-1 380	624
Other comprehensive income after tax		**64**	**-294**	**-1 380**	**624**
Total comprehensive income attributable to Parent Company's shareholders.		**-70 961**	**-98 881**	**-339 331**	**-1 429 693**
Earnings per share before/after dilution (SEK)		**-0,79**	**-1,31**	**-4,11**	**-19,00**

Condensed consolidated statement of financial position

SEK thousand	Note	2023-03-31	2022-03-31	2022-12-31	2021-12-31
ASSETS					
Non-current assets		20 023	29 862	21 289	27 003
Total non-current assets		**20 023**	**29 862**	**21 289**	**27 003**
Current assets					
Inventory		1 033	-	-	-
Current receivables		41 922	36 890	19 519	50 186
Short term investments		75 531	-	-	-
Cash		176 373	194 315	344 515	362 187
Total current assets		**296 859**	**231 205**	**364 034**	**412 373**
TOTAL ASSETS		**316 882**	**261 067**	**385 323**	**439 376**
EQUITY AND LIABILITIES					
Equity		228 422	119 128	294 293	210 868
Total Equity		**228 422**	**119 128**	**294 293**	**210 868**
Long-term liabilities		4 414	6 353	5 358	3 219
Total long-term liabilities		**4 414**	**6 353**	**5 358**	**3 219**
Current liabilities					
Trade payables		19 536	14 279	28 219	35 702
Other current liabilities		64 510	121 307	57 453	189 587
Total current liabilities		**84 046**	**135 586**	**85 672**	**225 289**
TOTAL EQUITY AND LIABILITIES		**316 882**	**261 067**	**385 323**	**439 376**

Condensed consolidated statement of changes in equity

SEK thousand	Note	2023 Jan-Mar	2022 Jan-Mar	2022 Jan-Dec	2021 Jan-Dec
Opening Balance		**294 293**	**210 868**	**210 868**	**576 897**
Net profit		-71 025	-98 587	-337 951	-1 430 317
Other comprehensive income		64	-294	-1 380	624
Total comprehensive income		**-70 961**	**-98 881**	**-339 331**	**-1 429 693**
Transactions with owners					
New issue of shares		-	-	436 015	1 106 000
Repurchase of shares		-	-	-438	-
Costs related to directed share issue		-	-	-27 667	-67 053
Share based compensation		5 090	7 106	14 812	14 229
Exercised warrants		-	34	34	10 488
Total transactions with owners		**5 090**	**7 141**	**422 756**	**1 063 664**
Ending balance		**228 422**	**119 128**	**294 293**	**210 868**

Condensed consolidated statement of cash flow

SEK thousand	Note	2023 Jan-Mar	2022 Jan-Mar	2022 Jan-Dec	2021 Jan-Dec
Operating activities					
Operating profit/loss		-72 740	-98 865	-349 350	-1 420 917
Adjustment for non-cash items		5 858	8 566	36 379	-44 325
Interest received		244	-	2 616	96
Interest paid		-134	-259	-883	-948
Taxes paid		-	6	-38	-12 216
Cash-flow from operating activities before change in working capital		**-66 772**	**-90 552**	**-311 276**	**-1 478 309**
Change in working capital		-22 225	-75 481	-109 233	-38 082
Cash-flow from operating activities		**-88 997**	**-166 033**	**-420 509**	**-1 516 391**
Cash-flow from investment activities		-	-	-2 507	-339
Cash-flow from financing activities		-1 806	-3 959	392 402	1 034 030
Cash-flow for the period		**-90 803**	**-169 992**	**-30 614**	**-482 701**
Cash at the beginning of the period		344 515	362 187	362 187	840 255
Change in cash		-90 803	-169 992	-30 614	-482 701
Effect of exchange rate changes on cash		192	2 120	12 942	4 633
Cash at the end of the period		**253 904**	**194 315**	**344 515**	**362 187**

Condensed Parent Company income statement

SEK thousand	Note	2023 Jan-Mar	2022 Jan-Mar	2022 Jan-Dec	2021 Jan-Dec
Net sales		1 124	-	560	97 577
Cost of Goods Sold		-11	-	-6	-12 182
Gross profit		**1 113**	**-**	**554**	**85 395**
Research and development expenses		-29 490	-65 930	-217 164	-676 375
Marketing and distribution expenses		-26 297	-15 339	-58 919	-728 382
Administrative expenses		-21 822	-20 392	-77 328	-161 814
Other operating income/expenses		2 639	-549	-67	71 362
Total operating expenses		**-74 970**	**-102 210**	**-353 478**	**-1 495 209**
EBIT; Operating profit/loss		**-73 857**	**-102 210**	**-352 924**	**-1 409 814**
Net financial items		599	4 729	28 825	-18 725
Earnings after net financial items		**-73 258**	**-97 481**	**-324 099**	**-1 428 539**
Group contribution		-1 538	-	-700	-
EBT; Earnings before taxes		**-74 796**	**-97 481**	**-324 799**	**-1 428 539**
Tax		-	-	-	-
Net profit		**-74 796**	**-97 481**	**-324 799**	**-1 428 539**

Condensed Parent Company statement of comprehensive income

SEK thousand	Note	2023 Jan-Mar	2022 Jan-Mar	2022 Jan-Dec	2021 Jan-Dec
EBT; Earnings before taxes		-74 796	-97 481	-324 799	-1 428 539
Other comprehensive income		-	-	-	-
Net profits		**-74 796**	**-97 481**	**-324 799**	**-1 428 539**

Parent Company balance sheet

SEK thousand	Note	2023-03-31	2022-03-31	2022-12-31	2021-12-31
ASSETS					
Non-current assets		11 067	11 940	11 671	12 910
Total non-current assets		**11 067**	**11 940**	**11 671**	**12 910**
Current assets					
Inventory		1 033	-	-	-
Current receivables		36 501	27 043	17 497	28 753
Short term investments		75 531	-	-	-
Cash		163 344	150 619	328 537	321 832
Total current assets		**276 409**	**177 662**	**346 034**	**350 585**
TOTAL ASSETS		**287 476**	**189 602**	**357 705**	**363 495**
EQUITY AND LIABILITIES					
Restricted equity		20 688	18 609	20 688	18 575
Non-restricted capital		212 215	95 704	281 922	186 078
Total Equity		**232 903**	**114 313**	**302 610**	**204 653**
Long-term liabilities		2 216	143	1 815	13
Total long-term liabilities		**2 216**	**143**	**1 815**	**13**
Current liabilities					
Trade payables		16 831	10 467	26 277	34 875
Other current liabilities		35 526	64 679	27 003	123 954
Total current liabilities		**52 357**	**75 146**	**53 280**	**158 829**
TOTAL EQUITY AND LIABILITIES		**287 476**	**189 602**	**357 705**	**363 495**

NOTE 1 - GENERAL INFORMATION

The interim report covers the Swedish parent company Oncopeptides AB (publ), Swedish corporate identity no. 556596-6438 and its fully owned subsidiaries Oncopeptides Incentive AB (and its wholly owned subsidiary Oncopeptides Innovation 1 AB), Oncopeptides GmbH, Germany and Oncopeptides Inc, USA. The parent company is a Swedish public limited company with its registered office in Stockholm. Numbers in parentheses in the report refer to the figures for the corresponding period the previous year. The year end report was approved for publication on May 4, 2023.

NOTE 2 - ACCOUNTING PRINCIPLES

The interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting. The parent company applies the Swedish Financial Reporting Board recommendation RFR2 Accounting for legal entities. Oncopeptides applies, except as described below, the same accounting principles as in the last Annual Report. Relevant accounting and valuation principles could be found on pages 50-54 of the Annual Report for 2022.

No new or amended standards that became effective January 1, 2023, have had a significant impact on the company's financial reporting.

Oncopeptides applies ESMA's (European Securities and Markets Authority) guidelines on alternative performance measures.

NOTE 3 - RISKS AND UNCERTAINTIES

Oncopeptides is exposed to a multitude of risk in its day-to-day operation, primarily regulatory, operational, financial, and credit risks. The company continuously assesses known and foreseeable risks and has integrated mitigating such risks as part of its short- and long-term business and sustainability strategy.
The company assesses that other risks remain as described in the 2022 annual report.

NOTE 4 - ESTIMATES AND CONSIDERATIONS

This report includes forward looking statements. Actual outcomes may vary from what has been stated. In addition, internal factors such as successful management of research projects, and intellectual property rights may affect future financial outcomes. Going concern as well as other external conditions such as, but not limited to, e.g., the economic climate, political changes and competing research projects that may affect Oncopeptides net profit. For more information see the Oncopeptides Annual report 2022.

NOTE 5 - REVENUE RECOGNITION

Revenue is recognized at the transaction price for goods sold, excluding value added tax, discounts and returns. Revenue is recognized at the time of delivery, when Oncopeptides has fulfilled its performance commitment and the control of the products are transferred to the customer. Customers are defined as hospitals and/or clinics and resellers who sell the products, at an intermediate stage, to the final user of the products. Since the final price is related to the discount which is valid on each local market and which is paid to the patients' insurance companies, the transaction price is not known upon delivery. This is regulated by booking a provision for the estimated discount in the Group, based on the framework for discounts which is valid on each market. The provision for estimated discounts is reported under the headline accrued expenses.

A provision for expected returns related to the withdrawal of Pepaxto from the US market in 2021, is reported at the closing date. The remaining provision is reported in the consolidated balance sheet under Other current liabilities and amounted to SEK 22.7 M at the end of the first quarter.

Group Revenue SEK thousand	2023 Jan-Mar	2022 Jan-Mar	2022 Jan-Dec	2021 Jan-Dec
Net sales				
Goods	1 124	-	8 355	118 295
Total net revenue	**1 124**	**-**	**8 355**	**118 295**
Geographic market				
USA	-	-	7 795	118 295
Germany	1 124	-	560	

Parent Company Revenue SEK thousand	2023 Jan-Mar	2022 Jan-Mar	2022 Jan-Dec	2021 Jan-Dec
Net sales				
Goods	1 124	-	560	97 577
Total net revenue	**1 124**	**-**	**560**	**97 577**
Geographic market				
USA	-	-	-	97 577
Germany	1 124	-	560	

NOTE 6 - RELATED PARTY TRANSACTIONS

Remuneration to senior management has been paid in accordance with current policies. No other transactions with related parties, outside of the Oncopeptides Group, occurred during the period.

NOTE 7 - SHARE BASED INCENTIVE PROGRAMS

The purpose of share-based incentive programs is to promote the company's long-term interests by motivating and rewarding the company's senior management, founders, and other co-workers in line with the interest of the shareholders. Oncopeptides has currently nine programs that include the management team, certain board members, founders and employees.

Program
- 2016; "Employee option program 2016/2023".
- 2017; "Co-worker LTIP 2017"
- 2018; "Co-worker LTIP 2018"
- 2019; "Co-worker LTIP 2019"
- 2020; "Board LTIP 2020"
- 2021; "Board LTIP 2021" and "Co-worker LTIP 2021"
- 2022; "Co-worker LTIP 2022" and "Board SHP 2022"

For more information on the programs see Note 26 in the Annual report 2022 as well as Agendas and Minutes from the relevant Annual General Meetings on the company's website www.oncopeptides.com.

At the end of the period, full utilization (including warrants for securing social security contributions), of
- Options and share awards resolved by the AGM and awarded to named individuals corresponding to 5,887,891 shares, would result in a dilution of 6.1 percent.
- Options and share awards resolved by the AGM and awarded to named individuals as well as those not yet awarded to individuals*, corresponding to 7,761,699 shares, would result in a dilution of 7.9 percent.

** "Options and share awards not yet awarded to individuals" refers to the C-shares related to Co-worker LTIP 2022 and held by the Company.*

NOTE 8 - SIGNIFICANT EVENTS AFTER THE PERIOD

- Oncopeptides issues warrants to utilize the first loan tranche from EIB.

Key performance measures

In this report, certain key performance measures are presented, including measures that are not defined under IFRS,

- Research and development / operating expenses, %,
- Gross margin, TSEK, %.

The company believes that these measurements provides valuable additional information when evaluating the company's economic trends. These financial performance measures should not be viewed in isolation, nor be considered in replacement of performance indicators that are prepared in accordance with IFRS.

Further, such performance measures, as the company has defined them, should not be compared with other performance measures with similar names used by other companies since definitions and calculation methods may vary between companies.

SEK Thousand	2023 Jan-Mar	2022 Jan-Mar	2022 Jan-Dec	2021 Jan-Dec
Net sales	1 124	-	8 355	118 295
Gross profit[1)]	1 113	-	8 349	65 174
Gross margin[2)]	99%	-	100%	55%
Registered common shares outstanding				
beginning of period	90 368 660	75 291 841	75 291 841	67 939 715
end of period	90 368 660	75 307 217	90 368 660	75 291 841
C-shares for LTI programs[3)]	3 940 607	-	3 940 607	-
Registered shares; end of period including C-shares	94 309 267	75 307 217	94 309 267	75 291 841
Share capital at the end of period	10 479	8 367	10 479	8 366
Equity at the end of period	228 422	119 128	294 293	210 868
Earnings per share before/after dilution, kr[4)]	-0,79	-1,31	-4,11	-19,00
Operating loss	-72 740	-98 865	-349 350	-1 420 917
Research and development expenses	-30 067	-65 828	-217 657	-679 926
R&D costs/operating expenses, %[5)]	41%	67%	61%	46%

1) Defined by subtracting cost of goods sold from total sales. The key figure shows gross profitability of cost of goods sold in absolute numbers.
2) Defined by dividing the sum of the company's gross profit by total sales. The key figure aims to clarify the relative profitability of goods sold.
3) For more information, please see the notice to the Annual General Meeting 2022.
4) Earnings per share before dilution are calculated by dividing earnings attributable to shareholders of the Parent Company by a weighted average number of outstanding shares during the period. There is no dilution effect driven by the employee stock option program, as earnings for the periods have been negative.
5) Defined by dividing the research and development costs with total operating expenses. The key performance measure provides an indication of the proportion of expenses that are attributable to the company's core business.

Telephone conference

The Interim report for the period and an operational update will be presented by CEO Monica Shaw and members of Oncopeptides Leadership team, Thursday May 4, 2023, at 09:00 (CET).

If you wish to participate via **webcast**, please use the link below. Through the webcast you can ask written questions.
https://ir.financialhearings.com/oncopeptides-q1-2023

If you wish to participate via **telephone conference**, please register on the link below. After registration you will be provided a phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://conference.financialhearings.com/teleconference/?id=200728

Financial Calendar

Report	Datum
Interim Q1 report 2023	4 May 2023
AGM 2023	25 May 2023
Interim Q2 report 2023	10 August 2023
Interim Q3 report 2023	8 November 2023

Contact

Oncopeptides AB
Visiting adress; Luntmakargatan 46, 111 37 Stockholm
Domicile: Västra Trädgårdsgatan 15, 111 53 Stockholm, Sweden

Telephone:
+46 8 615 20 40
E-mail: info@oncopeptides.com

Website: oncopeptides.com

Thesaurus

EMA	European Medicines Agency
CHMP	The European Medicines Agency's Committee for Medicinal Products for Human Use



This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on May 4, 2023.